Next-generation sequencing (NGS) enables researchers and drug developers to better understand the biology that drives cancer predisposition and proliferation. These insights have led to the development of targeted therapeutics and multi-analyte tumor analysis. This, in turn, has opened the door for novel methods to monitor cancer treatment and recurrence.
Illumina brings innovation to oncology drug development by offering comprehensive genomic solutions and working in collaboration with leading pharmaceutical providers.
As targeted therapies make their way through pharmaceutical pipelines, the need for comprehensive tumor profiling is increasing.Learn about our solution for companion diagnostic development »
NGS helps drug developers to explore genomic variation. This informs target discovery, validation, and clinical development.Learn more about our genomic solutions for drug development »
Watch Dr. Richard Klausner, CMO at Illumina, describe the company’s initiatives to transform the future of oncology with genomics.View Video »
Learn more about our pharmaceutical partnership strategy for development of oncology diagnostics.Access the Application Spotlight »
Get help in choosing the right genomics solution for you. Contact us »